<DOC>
	<DOC>NCT02836600</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.</brief_summary>
	<brief_title>A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic. In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate. Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale. Adequate organ function, including hematologic, hepatic, and renal. Estimated life expectancy of ≥12 weeks. Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively. Have serious preexisting medical conditions. Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea. Have an active bacterial, fungal, and/or known viral infection. Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>notch inhibitor</keyword>
</DOC>